One Year Results of the Effect of Intravitreal Ranibizumab on the Retinal Arteriolar Diameter in Patients with Neovascular Age-Related Macular Degeneration

2009 ◽  
Author(s):  
E. Mendrinos ◽  
G. Mangioris ◽  
D. Papadopoulou ◽  
G. Donati ◽  
C. Pournaras
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
One Year ◽  
Arteriolar Diameter ◽  
Retinal Arteriolar ◽  
Retinal Arteriolar Diameter

scholarly journals Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Juliana Wons ◽  
Magdalena A. Wirth ◽  
Nicole Graf ◽  
Matthias D. Becker ◽  
Stephan Michels
Keyword(s):  
Retinal Pigment Epithelium ◽  
Macular Degeneration ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Age Related Macular Degeneration ◽  
Progression Rate ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Significant Difference ◽  
One Year

Purpose. Retinal pigment epithelium (RPE) loss in neovascular age-related macular degeneration (nAMD) seem to have a linear progression but might be influenced by the treatment. The purpose of the study is the comparison of RPE loss over three years in patients treated with intravitreal ranibizumab to patients who were switched to aflibercept. Methods. A retrospective analysis with 96 eyes switched to aflibercept was conducted. The progression rate of RPE loss was evaluated in patients who showed atrophy one year prior to switch (n=17) or on switch date (n=19). The RPE loss was evaluated by spectral domain optical coherence tomography (SD-OCT). Further, 22 eyes from patients treated with ranibizumab were compared. Results. The median yearly progression of RPE loss after square root transformation showed no significant difference in the year prior to switch compared to the year after switch (p=0.854). In patients who received only ranibizumab, the median yearly progression of RPE loss was 0.15 mm/y, for aflibercept patients, 0.13 mm/y. This difference was not statistically significant (p=0.172). Conclusions. There seems to be a linear progression rate of RPE loss in patients treated with ranibizumab as well as in patients with aflibercept. No significant increase of progression rate was found after switch to aflibercept.

scholarly journals One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Tomoko Nakamura ◽  
Akio Miyakoshi ◽  
Kazuya Fujita ◽  
Tatsuya Yunoki ◽  
Keiichi Mitarai ◽  
...  
Keyword(s):  
Photodynamic Therapy ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
One Year

Intravitreal Ranibizumab May Induce Retinal Arteriolar Vasoconstriction in Patients with Neovascular Age-related Macular Degeneration

Ophthalmology ◽  
2009 ◽  
Vol 116 (9) ◽  
pp. 1755-1761 ◽  
Author(s):  
Domniki N. Papadopoulou ◽  
Efstratios Mendrinos ◽  
Georgios Mangioris ◽  
Guy Donati ◽  
Constantin J. Pournaras
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Retinal Arteriolar
Sign in / Sign up

Export Citation Format

Share Document